Drug Trial Radar · NCT07230288
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
165
Planned (sponsor's estimate)
Start
Jan 23, 2026
Primary completion
Sep 2029
Study completion Sep 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1). ABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is "double-blind", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world. Participants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
ABBV-142Drug
ABBV-142
Placebo for ABBV-142Drug
Placebo for ABBV-142
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL)Time frame: Week 24
- Percentage of Participants with Adverse Events (AE)Time frame: Up to approximately 52 weeks
Locations
57 sites in 17 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham /ID# 277613
Birmingham, Alabama · Recruiting
Sec Clinical Research - East - Dothan - Graceland /ID# 278328
Dothan, Alabama · Recruiting
Clinical Research Specialists - Kissimmee /ID# 279184
Kissimmee, Florida · Recruiting
Christie Clinic on University /ID# 277871
Champaign, Illinois · Recruiting
University of Michigan Health System - Ann Arbor /ID# 279994
Ann Arbor, Michigan · Recruiting
Henry Ford Hospital /ID# 277843
Detroit, Michigan · Recruiting
Hannibal Regional Hospital /ID# 277984
Hannibal, Missouri · Recruiting
Jefferson Health Honickman Center /ID# 279127
Philadelphia, Pennsylvania · Recruiting
Inova Fairfax Hospital /ID# 278469
Falls Church, Virginia · Recruiting
Virginia Commonwealth University Medical Center /ID# 277992
Richmond, Virginia · Recruiting
Lung Research Queensland /ID# 278838
Nundah, Queensland, Australia · Recruiting
Eastern Health /ID# 278245
Box Hill, Victoria, Australia · Recruiting
University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 277845
Pleven, Bulgaria · Recruiting
University Multiprofile Hospital For Active Treatment Sveti Georgi - Plovdiv /ID# 279367
Plovdiv, Bulgaria · Recruiting
Acibadem City Clinic Tokuda University Hospital EAD /ID# 277846
Sofia, Bulgaria · Recruiting
Diagnostic Consultative Center Convex /ID# 277848
Sofia, Bulgaria · Recruiting
Diagnostic Consultative Center Convex /ID# 277849
Sofia, Bulgaria · Recruiting
Centre d'Investigation Clinique Mauricie /ID# 277949
Trois-Rivières, Quebec, Canada · Recruiting
Hopital Arnaud de Villeneuve /ID# 278322
Montpellier, Herault, France · Recruiting
Hopital Avicenne /ID# 279212
Bobigny, Île-de-France Region, France · Recruiting
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou /ID# 278333
Rennes, Ille-et-Vilaine, France · Recruiting
Klinikum Konstanz /ID# 278139
Konstanz, Baden-Wurttemberg, Germany · Recruiting
Caritas-Krankenhaus St. Maria gGmbH /ID# 278138
Donaustauf, Bavaria, Germany · Recruiting
University Hospital of Ioannina /ID# 277719
Ioannina, Greece · Recruiting
General Hospital of Thessaloniki George Papanikolaou /ID# 277819
Thessaloniki, Greece · Recruiting
University General Hospital of Patras /ID# 277726
Pátrai, Achaia, Greece · Recruiting
General Hospital of Chest Diseases of Athens SOTIRIA /ID# 277724
Athens, Attica, Greece · Recruiting
University General Hospital of Heraklion /ID# 277717
Heraklion, Crete, Greece · Recruiting
NHO Kinki Chuo Chest Medical Center /ID# 280225
Sakai-shi, Osaka, Japan · Recruiting
Vitamed Galaj i Cichomski Sp.j. /ID# 278145
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting
Unidade Local de Saude do Algarve, EPE /ID# 278388
Faro, Portugal · Recruiting
Unidade Local de Saude de Loures-Odivelas-Hospital Beatriz Angelo /ID# 278357
Loures, Lisbon District, Portugal · Recruiting
Unidade Local de Saude de Matosinhos EPE /ID# 277980
Senhora da Hora, Porto District, Portugal · Recruiting
University Clinical Center Serbia /ID# 278496
Belgrade, Beograd, Serbia · Recruiting
Institute For Pulmonary Diseases Of Vojvodina /ID# 278499
Kamenitz, Sremski Okrug, Serbia · Recruiting
Dr Hannes J van Rensburg inc /ID# 278278
Cape Town, Western Cape, South Africa · Recruiting
Dr JM Engelbrecht Trial Site /ID# 278287
Somerset West, Western Cape, South Africa · Recruiting
Inje University Haeundae Paik Hospital /ID# 278000
Busan, Busan Gwang Yeogsi, South Korea · Recruiting
The Catholic University Of Korea, Bucheon St. Mary'S Hospital /ID# 278068
Bucheon-si, Gyeonggido, South Korea · Recruiting
Seoul National University Bundang Hospital /ID# 278059
Seongnam-si, Gyeonggido, South Korea · Recruiting
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.